{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:13:21Z","timestamp":1791486801470,"version":"4.3.4"},"reference-count":62,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1124\/jpet.114.218164","type":"journal-article","created":{"date-parts":[[2014,9,25]],"date-time":"2014-09-25T06:30:01Z","timestamp":1411626601000},"page":"538-548","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["The Novel Kinase Inhibitor PRT062070 (Cerdulatinib) Demonstrates Efficacy in Models of Autoimmunity and B-Cell Cancer"],"prefix":"10.1016","volume":"351","author":[{"given":"Greg","family":"Coffey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Betz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"DeGuzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Pak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayuko","family":"Inagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale C.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley J.","family":"Hollenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.114.218164_bib1","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"10.1124\/jpet.114.218164_bib2","doi-asserted-by":"crossref","first-page":"32662","DOI":"10.1074\/jbc.274.46.32662","article-title":"SYK is upstream of phosphoinositide 3-kinase in B cell receptor signaling","volume":"274","author":"Beitz","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.114.218164_bib3","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1124\/jpet.106.109058","article-title":"R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation","volume":"319","author":"Braselmann","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.114.218164_bib4","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/intimm\/14.4.411","article-title":"IFN-alpha\/beta enhances BCR-dependent B cell responses","volume":"14","author":"Braun","year":"2002","journal-title":"Int Immunol"},{"key":"10.1124\/jpet.114.218164_bib5","doi-asserted-by":"crossref","unstructured":"Brown JR, Furman RR, Flinn I, Coutre SE, Wagner-Johnston ND, Kahl BS, Spurgeon SEF, Benson DM, Peterman S, Johnson DM, et al. (2013) Final results of a phase I study of idelalisib (GS-1101) a selective inhibitor of PI3K\u03b4, in patients with relapsed or refractory CLL. J Clin Oncol 31 (Suppl) 7003.","DOI":"10.1200\/jco.2013.31.15_suppl.7003"},{"key":"10.1124\/jpet.114.218164_bib6","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2009-07-233692","article-title":"Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia","volume":"115","author":"Buchner","year":"2010","journal-title":"Blood"},{"key":"10.1124\/jpet.114.218164_bib7","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.114.218164_bib8","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/(SICI)1097-0320(19991015)38:5<224::AID-CYTO4>3.0.CO;2-0","article-title":"Modulation of apoptosis by cytokines in B-cell chronic lymphocytic leukemia","volume":"38","author":"Castej\u00f3n","year":"1999","journal-title":"Cytometry"},{"key":"10.1124\/jpet.114.218164_bib9","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1182\/blood-2011-02-333773","article-title":"SYK inhibition and response prediction in diffuse large B-cell lymphoma","volume":"118","author":"Cheng","year":"2011","journal-title":"Blood"},{"key":"10.1124\/jpet.114.218164_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1196\/annals.1358.002","article-title":"B-cell chronic lymphocytic leukemia, a clonal disease of B lymphocytes with receptors that vary in specificity for (auto)antigens","volume":"1062","author":"Chiorazzi","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.1124\/jpet.114.218164_bib11","doi-asserted-by":"crossref","first-page":"3873","DOI":"10.4049\/jimmunol.143.12.3873","article-title":"Activation of human B cells. Comparison of the signal transduced by IL-4 to four different competence signals","volume":"143","author":"Clark","year":"1989","journal-title":"J Immunol"},{"key":"10.1124\/jpet.114.218164_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/prp2.16","article-title":"Methotrexate and a spleen tyrosine kinase inhibitor cooperate to inhibit responses to peripheral blood B cells in rheumatoid arthritis","volume":"1","author":"Coffey","year":"2013","journal-title":"Pharmacology Research and Perspectives"},{"key":"10.1124\/jpet.114.218164_bib13","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1124\/jpet.111.188441","article-title":"Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis","volume":"340","author":"Coffey","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.114.218164_bib14","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.4049\/jimmunol.1000983","article-title":"Therapeutic targeting of Syk in autoimmune diabetes","volume":"185","author":"Colonna","year":"2010","journal-title":"J Immunol"},{"key":"10.1124\/jpet.114.218164_bib15","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1084\/jem.176.5.1319","article-title":"Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression","volume":"176","author":"Dancescu","year":"1992","journal-title":"J Exp Med"},{"key":"10.1124\/jpet.114.218164_bib16","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"10.1124\/jpet.114.218164_bib17","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1182\/blood-2007-04-087734","article-title":"Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas","volume":"111","author":"Ding","year":"2008","journal-title":"Blood"},{"key":"10.1124\/jpet.114.218164_bib18","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nature11309","article-title":"Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling","volume":"489","author":"D\u00fchren-von Minden","year":"2012","journal-title":"Nature"},{"key":"10.1124\/jpet.114.218164_bib19","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF03167070","article-title":"Serum IL-10 and IL-6 levels at diagnosis as independent predictors of outcome in non-Hodgkin\u2019s lymphoma","volume":"60","author":"el-Far","year":"2004","journal-title":"J Physiol Biochem"},{"key":"10.1124\/jpet.114.218164_bib20","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.4049\/jimmunol.1100341","article-title":"Deletion of Syk in neutrophils prevents immune complex arthritis","volume":"187","author":"Elliott","year":"2011","journal-title":"J Immunol"},{"key":"10.1124\/jpet.114.218164_bib21","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1182\/blood.V97.1.256","article-title":"Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome","volume":"97","author":"Fayad","year":"2001","journal-title":"Blood"},{"issue":"Suppl","key":"10.1124\/jpet.114.218164_bib22","first-page":"5s","article-title":"Pharmacokinetics and pharmacodynamics of the dual Syk\/Jak inhibitor PRT062070 (Cerdulatinib) in patients with advanced B cell malignancies","volume":"32","author":"Flinn","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.114.218164_bib23","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.4049\/jimmunol.0902819","article-title":"Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050","volume":"184","author":"Fridman","year":"2010","journal-title":"J Immunol"},{"key":"10.1124\/jpet.114.218164_bib24","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"key":"10.1124\/jpet.114.218164_bib25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-2172-8-31","article-title":"Spleen tyrosine kinase Syk is critical for sustained leukocyte adhesion during inflammation in vivo","volume":"8","author":"Frommhold","year":"2007","journal-title":"BMC Immunol"},{"key":"10.1124\/jpet.114.218164_bib26","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1600-0609.1999.tb01766.x","article-title":"Somatic mutations and intraclonal variations in the rearranged Vkappa genes of B-non-Hodgkin\u2019s lymphoma cell lines","volume":"63","author":"Gabay","year":"1999","journal-title":"Eur J Haematol"},{"key":"10.1124\/jpet.114.218164_bib27","doi-asserted-by":"crossref","first-page":"e42610","DOI":"10.1371\/journal.pone.0042610","article-title":"Src kinase and Syk activation initiate PI3K signaling by a chimeric latent membrane protein 1 in Epstein-Barr virus (EBV)+ B cell lymphomas","volume":"7","author":"Hatton","year":"2012","journal-title":"PLoS ONE"},{"issue":"Suppl","key":"10.1124\/jpet.114.218164_bib28","doi-asserted-by":"crossref","first-page":"8523","DOI":"10.1200\/jco.2013.31.15_suppl.8523","article-title":"A phase I study of ISIS 481464 (AZD9150), a first-in-human, first-in-class, antisense oligonucleotide inhibitor of STAT3, in patients with advanced cancers","volume":"31","author":"Hong","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.114.218164_bib29","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/art.27438","article-title":"Genetic deficiency of Syk protects mice from autoantibody-induced arthritis","volume":"62","author":"Jakus","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1124\/jpet.114.218164_bib30","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1365-2141.1994.tb05017.x","article-title":"Interferon-alpha up-regulates bcl-2 expression and protects B-CLL cells from apoptosis in vitro and in vivo","volume":"88","author":"Jewell","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1124\/jpet.114.218164_bib31","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1084\/jem.188.7.1297","article-title":"Different protein tyrosine kinases are required for B cell antigen receptor-mediated activation of extracellular signal-regulated kinase, c-Jun NH2-terminal kinase 1, and p38 mitogen-activated protein kinase","volume":"188","author":"Jiang","year":"1998","journal-title":"J Exp Med"},{"key":"10.1124\/jpet.114.218164_bib32","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1158\/1078-0432.CCR-12-3349","article-title":"A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease","volume":"19","author":"Kurzrock","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1124\/jpet.114.218164_bib33","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/cncr.10772","article-title":"Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia","volume":"95","author":"Lai","year":"2002","journal-title":"Cancer"},{"key":"10.1124\/jpet.114.218164_bib34","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1182\/blood-2007-09-111948","article-title":"Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-kappaB pathways in subtypes of diffuse large B-cell lymphoma","volume":"111","author":"Lam","year":"2008","journal-title":"Blood"},{"key":"10.1124\/jpet.114.218164_bib35","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1182\/blood.V122.21.1833.1833","article-title":"Dual SYK\/JAK inhibition has a broader anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma","volume":"122","author":"Ma","year":"2013","journal-title":"Blood"},{"key":"10.1124\/jpet.114.218164_bib36","first-page":"453634","article-title":"Gene expression and serum cytokine profiling of low stage CLL identify WNT\/PCP, Flt-3L\/Flt-3 and CXCL9\/CXCR3 as regulators of cell proliferation, Survival and Migration","volume":"2009","author":"Mahadevan","year":"2009","journal-title":"Hum Genomics Proteomics"},{"key":"10.1124\/jpet.114.218164_bib37","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nri2765","article-title":"The SYK tyrosine kinase: a crucial player in diverse biological functions","volume":"10","author":"M\u00f3csai","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1124\/jpet.114.218164_bib38","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S1074-7613(02)00303-5","article-title":"Syk is required for integrin signaling in neutrophils","volume":"16","author":"M\u00f3csai","year":"2002","journal-title":"Immunity"},{"key":"10.1124\/jpet.114.218164_bib39","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood-2004-07-2947","article-title":"Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response","volume":"105","author":"Monti","year":"2005","journal-title":"Blood"},{"key":"10.1124\/jpet.114.218164_bib40","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.4049\/jimmunol.139.7.2172","article-title":"Polyclonal activation of the murine immune system by an antibody to IgD. VIII. Stimulation of IgD secretion","volume":"139","author":"Mountz","year":"1987","journal-title":"J Immunol"},{"key":"10.1124\/jpet.114.218164_bib41","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/intimm\/dxs078","article-title":"Syk-dependent signaling pathways in neutrophils and macrophages are indispensable in the pathogenesis of anti-collagen antibody-induced arthritis","volume":"24","author":"Ozaki","year":"2012","journal-title":"Int Immunol"},{"key":"10.1124\/jpet.114.218164_bib42","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2141.1993.tb03330.x","article-title":"Interleukin-4 inhibits apoptotic cell death and loss of the bcl-2 protein in B-chronic lymphocytic leukaemia cells in vitro","volume":"85","author":"Panayiotidis","year":"1993","journal-title":"Br J Haematol"},{"key":"10.1124\/jpet.114.218164_bib43","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1365-2133.2012.11168.x","article-title":"Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study","volume":"167","author":"Papp","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1124\/jpet.114.218164_bib44","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.clim.2007.03.543","article-title":"Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor","volume":"124","author":"Pine","year":"2007","journal-title":"Clin Immunol"},{"key":"10.1124\/jpet.114.218164_bib45","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1182\/blood-2008-07-166439","article-title":"Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk","volume":"113","author":"Podolanczuk","year":"2009","journal-title":"Blood"},{"key":"10.1124\/jpet.114.218164_bib46","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1182\/blood-2010-03-274969","article-title":"PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model","volume":"117","author":"Reilly","year":"2011","journal-title":"Blood"},{"key":"10.1124\/jpet.114.218164_bib47","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.114.218164_bib48","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1182\/blood.V122.21.1634.1634","article-title":"Phase 2 trial of GS-9973, a selective Syk inhibitor, in chronic lymphocytic leukemia (CLL) and non-hodgkin lymphoma (NHL)","volume":"642","author":"Sharman","year":"2013","journal-title":"Blood"},{"key":"10.1124\/jpet.114.218164_bib49","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1124\/jpet.112.200832","article-title":"The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia","volume":"344","author":"Spurgeon","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.114.218164_bib50","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2009-09-245811","article-title":"The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment","volume":"116","author":"Steele","year":"2010","journal-title":"Blood"},{"key":"10.1124\/jpet.114.218164_bib51","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1111\/j.1600-6143.2012.04127.x","article-title":"Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year","volume":"12","author":"Vincenti","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1124\/jpet.114.218164_bib52","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1084\/jem.160.5.1450","article-title":"Expression of interleukin 2 receptors on activated human B cells","volume":"160","author":"Waldmann","year":"1984","journal-title":"J Exp Med"},{"key":"10.1124\/jpet.114.218164_bib53","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.114.218164_bib54","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1002\/art.23992","article-title":"Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial","volume":"58","author":"Weinblatt","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1124\/jpet.114.218164_bib55","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1000500","article-title":"An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis","volume":"363","author":"Weinblatt","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.114.218164_bib56","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1002\/eji.201141502","article-title":"Induced Syk deletion leads to suppressed allergic responses but has no effect on neutrophil or monocyte migration in vivo","volume":"41","author":"Wex","year":"2011","journal-title":"Eur J Immunol"},{"key":"10.1124\/jpet.114.218164_bib57","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood.V120.21.686.686","article-title":"The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed\/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study","volume":"120","author":"Wilson","year":"2012","journal-title":"Blood"},{"key":"10.1124\/jpet.114.218164_bib58","doi-asserted-by":"crossref","first-page":"9991","DOI":"10.1073\/pnas.1732008100","article-title":"A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma","volume":"100","author":"Wright","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.114.218164_bib59","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/gb-2004-5-12-253","article-title":"The Janus kinases (Jaks)","volume":"5","author":"Yamaoka","year":"2004","journal-title":"Genome Biol"},{"key":"10.1124\/jpet.114.218164_bib60","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1182\/blood-2011-03-342436","article-title":"Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia","volume":"118","author":"Yan","year":"2011","journal-title":"Blood"},{"key":"10.1124\/jpet.114.218164_bib61","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1200\/JCO.2012.42.5223","article-title":"Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.114.218164_bib62","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1084\/jem.160.4.1170","article-title":"Activated B cells express receptors for, and proliferate in response to, pure interleukin 2","volume":"160","author":"Zubler","year":"1984","journal-title":"J Exp Med"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524188714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524188714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.114.218164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T17:55:31Z","timestamp":1739987731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524188714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0022356524188714"],"URL":"https:\/\/doi.org\/10.1124\/jpet.114.218164","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Novel Kinase Inhibitor PRT062070 (Cerdulatinib) Demonstrates Efficacy in Models of Autoimmunity and B-Cell Cancer","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.114.218164","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2014 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}